Browse Integrative Medicine Articles by Topic

Low-Dose Aspirin in the Primary Prevention of Cancer

By Barbara A. Phillips, MD, MSPH Professor of Medicine, University of Kentucky; Director, Sleep Disorders Center, Samaritan Hospital, Lexington, KY Dr. Phillips serves on the speakers bureau of Cephalon, Boehringer Ingelheim, Merck, ResMed, and GlaxoSmithKline and is a consultant for Boehringer Ingelheim, Wyeth-Ayerst, and ResMed. Synopsis: There was no overall effect of 100 mg aspirin every other day on total cancer among nearly 40,000 women randomized to aspirin or placebo and followed for an average of 10 years.

Clinical Briefs

Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment Foot Small Muscle Atrophy Before the Detection of Clinical Neuropathy Statins and the Risk of Colorectal Cancer

Etiology of Elevated Troponin Levels Other Than in Acute Coronary Syndromes

By Harold L. Karpman, MD Clinical Professor of Medicine, UCLA School of Medicine Dr. Karpman reports no financial relationship to this field of study.

Autonomic Peripheral Neuropathy

By Norm Latov, MD Professor of Neurology and Neuroscience and Director of the Peripheral Neuropathy Center at Weill Medical College at Cornell University. Dr. Latov is a consultant for Quest Diagnostics and Talecris Inc., is a stockholder of Therapath LLC, and has royalties in Athena Diagnostics. Synopsis: The availability of sensitive and reproducible measures of autonomic function has improved physicians ability to diagnose these disorders.

Pharmacology Update Medroxyprogesterone Acetate Injection (depo-subQ provera 104)

By William T. Elliott, MD, FACP, and James Chan, PhD, PharmD Dr. Elliott is Chair, Formulary Committee, Northern California Kaiser Permanente; Associate Clinical Professor of Medicine, University of California, San Francisco; Dr. Chan is Pharmacy Quality and Outcomes Manager, Kaiser Permanente, Oakland, CA. Drs. Chan and Elliott report no financial relationships to this field of study.

Treatment of Tuberculosis and Latent Tuberculosis Infection

The treatment of pulmonary tuberculosis is divided into an initial phase of four drugs for two months.

Treatment Alternatives for Chronic Hepatitis B Virus Infection: A Cost-Effectiveness Analysis

By Malcolm Robinson, MD, FACP, FACG Emeritus Clinical Professor of Medicine, University of Oklahoma College of Medicine, Oklahoma City, OK Dr. Robinson serves as a consultant for TAP, Pfizer, Janssen, Eisai, J&J-Merck, and Procter & Gamble, is on the speakers bureau of Janssen, Eli Lilly, Solvay, TAP, and Aventis, and does research for Forest Labs, Wyeth-Ayerst, AstraZeneca, and Centocor.

Pramlintide Acetate Injection (Symlin)

By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Chair, Formulary Committee, Northern California Kaiser Permanente; Associate Clinical Professor of Medicine, University of California, San Francisco; Dr. Chan is Pharmacy Quality and Outcomes Manager, Kaiser Permanente, Oakland, CA. Drs. Chan and Elliott report no financial relationships to this field of study. A synthetic analog of human amylin has been approved for the treatment of type 1 and type 2 diabetics. Pramlintide is a 37-amino acid peptide which differs from human amylin with substitution of three amino acids at positions 25, 28, and 29. It represents the first of a new class of amylinomimetic antidiabetic compounds. It is marketed by Amylin Pharmaceuticals, Inc as Symlin.

Full July 15, 2005, Issue in PDF

Rifamixin for the Prevention of Traveler’s Diarrhea?

Rifamixin, a nonabsorbed oral antibiotic, is effective for preventing traveler's diarrhea, according to new research.